CNS-specific Therapy for Ongoing EAE by Silencing IL-17 Pathway in Astrocytes
Open Access
- 1 July 2012
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 20 (7) , 1338-1348
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Signaling of interleukin-17 family cytokines in immunity and inflammationCellular Signalling, 2011
- The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSFNature Immunology, 2011
- Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis?Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Reversible neural stem cell niche dysfunction in a model of multiple sclerosisAnnals of Neurology, 2010
- Astrocyte-Restricted Ablation of Interleukin-17-Induced Act1-Mediated Signaling Ameliorates Autoimmune EncephalomyelitisImmunity, 2010
- Lentiviral Vectors in Gene Therapy: Their Current Status and Future PotentialArchivum Immunologiae et Therapiae Experimentalis, 2010
- Astrocytes in multiple sclerosis: A product of their environmentCellular and Molecular Life Sciences, 2008
- Multiple sclerosis: a complicated picture of autoimmunityNature Immunology, 2007
- Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosisJournal of Neuroimmunology, 2007
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003